Piper Jaffray analyst Matt O'Brien believes MiMedx has one of the best products for treating Venous Leg Ulcers, or VLUs, and he sees the publication of their latest peer-reviewed clinical study as "more ammunition" as the company lobbies insurance providers to pay in these cases. With peer-reviewed data in hand, he sees the company announcing positive coverage decisions in the coming quarters, he tells investors. O'Brien keeps an Overweight rating on MiMedx and recommends investors get "increasingly aggressive" on any pullbacks.

BTIG notes that seven Medicare Administrative Contractors, or MACs - CGS, WPS, NGS, Palmetto, Novitas, First Coast, and Noridian - this morning published new proposed local coverage determinations, or LCDs, regarding the coverage of skin substitutes grafts and cellular and tissue based products for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. This marks "the second attempt in the past 12 months where MACs have proposed an LCD that would drastically shake up the advanced wound care market," says the analyst, who highlights that the proposed LCD includes non-coverage products from Integra Lifesciences (IART), Organogenesis (ORGO), Smith & Nephew (SNN), MiMedx (MDXG), Anika Therapeutics (ANIK) and numerous smaller, private wound care companies. The firm adds that it thinks Integra and Organogenesis both have meaningful exposure to the LCDs based on their product portfolio and the revenue mix within their Advanced Wound Care businesses.